LGND — Ligand Pharmaceuticals Share Price
Last trade - 00:00- $2.08bn
- $1.83bn
- $167.13m
- 85
- 21
- 92
- 73
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 16.9 | ||
| PEG Ratio (f) | 0.28 | ||
| EPS Growth (f) | 152.25% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.51 | ||
| Price to Tang. Book | 7.62 | ||
| Price to Free Cashflow | 21.88 | ||
| Price to Sales | 12.47 | ||
| EV to EBITDA | 65.96 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.5% | ||
| Return on Equity | -0.53% | ||
| Operating Margin | -13.53% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 186.42 | 277.13 | 196.25 | 131.31 | 167.13 | 190.84 | 227.95 | 6.8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | -70.39 | +606.66 | +14.22 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Directors
- John Kozarich NEC (71)
- Matthew Foehr PRE (48)
- John Higgins CEO (51)
- Matthew Korenberg CFO (46)
- Charles Berkman SVP (52)
- Jason Aryeh IND (52)
- Sarah Boyce IND (49)
- Jennifer Cochran IND (49)
- Todd Davis IND (60)
- Nancy Gray IND (61)
- John Lamattina IND (71)
- Sunil Patel IND (49)
- Stephen Sabba IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 28th, 1987
- Public Since
- November 18th, 1992
- No. of Shareholders
- 320
- No. of Employees
- 68
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 19,280,962
- Address
- 3911 Sorrento Valley Blvd, Suite 110, SAN DIEGO, 92121
- Web
- https://www.ligand.com/
- Phone
- +1 8585507500
- Auditors
- Ernst & Young LLP
Latest News for LGND
Upcoming Events for LGND
Q1 2025 Ligand Pharmaceuticals Inc Earnings Call
Q1 2025 Ligand Pharmaceuticals Inc Earnings Release
Ligand Pharmaceuticals Inc Annual Shareholders Meeting
Ligand Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Ligand Pharmaceuticals Inc Earnings Release
Similar to LGND
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
As of Today at 21:45 UTC, shares in Ligand Pharmaceuticals are trading at $108.07. This share price information is delayed by 15 minutes.
Shares in Ligand Pharmaceuticals last closed at $108.07 and the price had moved by +53.57% over the past 365 days. In terms of relative price strength the Ligand Pharmaceuticals share price has outperformed the S&P500 Index by +41.75% over the past year.
The overall consensus recommendation for Ligand Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreLigand Pharmaceuticals does not currently pay a dividend.
Ligand Pharmaceuticals does not currently pay a dividend.
Ligand Pharmaceuticals does not currently pay a dividend.
To buy shares in Ligand Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $108.07, shares in Ligand Pharmaceuticals had a market capitalisation of $2.08bn.
Here are the trading details for Ligand Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: LGND
Based on an overall assessment of its quality, value and momentum Ligand Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Ligand Pharmaceuticals is $143.50. That is 32.78% above the last closing price of $108.07.
Analysts covering Ligand Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $6.12 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ligand Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +1.86%.
As of the last closing price of $108.07, shares in Ligand Pharmaceuticals were trading -0.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ligand Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 16.9. The shares last closed at $108.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ligand Pharmaceuticals' management team is headed by:
- John Kozarich - NEC
- Matthew Foehr - PRE
- John Higgins - CEO
- Matthew Korenberg - CFO
- Charles Berkman - SVP
- Jason Aryeh - IND
- Sarah Boyce - IND
- Jennifer Cochran - IND
- Todd Davis - IND
- Nancy Gray - IND
- John Lamattina - IND
- Sunil Patel - IND
- Stephen Sabba - IND